331 related articles for article (PubMed ID: 27023686)
21. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Lertnawapan R; Jatuworapruk K
Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of allopurinol and febuxostat for the management of gout.
Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM
Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883
[TBL] [Abstract][Full Text] [Related]
23. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
24. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
[TBL] [Abstract][Full Text] [Related]
25. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
[TBL] [Abstract][Full Text] [Related]
26. A lifetime economic research of universal HLA-B*58:01 genotyping or febuxostat initiation therapy in Chinese gout patients with mild to moderate chronic kidney disease.
Hong Y; Chen X; Li Z; Zhang X; Zhou C; Wang Y; Wang G; Wu W; Zhou D; Feng Li H
Pharmacogenet Genomics; 2023 Feb; 33(2):24-34. PubMed ID: 36729770
[TBL] [Abstract][Full Text] [Related]
27. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Jackson RL; Hunt B; MacDonald PA
BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
[TBL] [Abstract][Full Text] [Related]
29. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
[TBL] [Abstract][Full Text] [Related]
31. Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor.
Foody J; Turpin RS; Tidwell BA; Lawrence D; Schulman KL
Am Health Drug Benefits; 2017 Nov; 10(8):393-401. PubMed ID: 29263773
[TBL] [Abstract][Full Text] [Related]
32. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.
Kim SC; Schmidt BM; Franklin JM; Liu J; Solomon DH; Schneeweiss S
Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2008-14. PubMed ID: 23861232
[TBL] [Abstract][Full Text] [Related]
33. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of febuxostat in chronic gout.
Beard SM; von Scheele BG; Nuki G; Pearson IV
Eur J Health Econ; 2014 Jun; 15(5):453-63. PubMed ID: 23719971
[TBL] [Abstract][Full Text] [Related]
35. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
37. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
[TBL] [Abstract][Full Text] [Related]
38. Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis.
Hsu YO; Wu IW; Chang SH; Lee CC; Tsai CY; Lin CY; Lin WT; Huang YT; Wu CY; Kuo G; Hsiao CY; Lin HL; Yang CC; Yen TH; Chen YC; Hung CC; Tian YC; Kuo CF; Yang CW; Anderson GF; Yang HY
Clin Pharmacol Ther; 2020 May; 107(5):1159-1169. PubMed ID: 31628864
[TBL] [Abstract][Full Text] [Related]
39. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
40. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
van de Laar CJ; Janssen CA; Janssen M; Oude Voshaar MAH; Al MJ; van de Laar MAFJ
PLoS One; 2022; 17(1):e0261940. PubMed ID: 35089941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
